19 COVID-19” issued together with Decision 250/QD-BYT dated January 28, 2022 of the Minister of Health. Accordingly, the Ministry of Health has issued guidelines related to the use of antiviral drugs.

The Ministry of Health has supplemented guidelines for the use of Molnupiravir and Remdesivir in the treatment of COVID-19

Specifically, in the Summary table of principles for treating COVID-19 patients, additional content about the drug Molnupiravir: Drugs used for people with symptoms mild and moderate symptoms. Patients with asymptomatic or mild COVID-19 infection can be treated at home or at COVID-19 treatment facilities depending on the epidemic situation in each locality. There is medical supervision. The Ministry of Health has added guidelines for the use of two antiviral drugs in the treatment of COVID-19 as follows:

1- Remdesivir is indicated in the following cases:

 - Inpatient, mild disease and has at least one risk factors for severe progression; moderate and severe severity, disease onset less than 10 days with respiratory failure requiring oxygen, HFNC, non-invasive mechanical ventilation.

- Should be combined with corticosteroids (preferably dexamethasone).

- For cases treated with remdesivir before invasive ventilation or ECMO, remdesivir can be continued for the full course. Contraindicated with a history of hypersensitivity to any ingredient in the formulation.

- Patients with liver enzymes ALT increased more than 5 times the upper limit of the normal range Dosage: People ≥12 years old and weighing >40 kg: 200 mg on the first day, 100 mg/day in the following days, intravenously once in a day 30 - 120 minutes.

- Pregnant and breastfeeding women: There are no adequate data. Not recommended unless benefits outweigh risks.

- Monitor patients during infusion and within 1 hour after infusion to detect and promptly handle anaphylaxis and infusion reactions (if any).

- Monitor liver enzyme elevation during drug use. Discontinue use if ALT rises above 5 times the upper limit of normal during treatment.

- There is not enough information to recommend the use of the drug for patients with estimated glomerular filtration rate eGFR < 30 mL/min).

- For more detailed information about the drug, follow the instructions for use of the drug.

2- Molnupiravir:

- For use in adult COVID-19 patients 18 years of age and older with mild to moderate disease and at least one risk factor for severe disease progression.

- Drugs used within 5 days of symptom onset or positive test result. Hospitalized patients who have been previously initiated on molnupiravir may continue to take the drug to complete a 5 day regimen at the discretion of the treating physician.

- Treatment duration: 5 days

Notes:

- Not recommended for use in pregnant women, lactating women, children under 18 years old due to concerns about the risk of toxicity on the fetus, on bones and cartilage of the fetus. medicine.
Women of childbearing potential and women of childbearing potential should use appropriate and effective contraception during treatment and for 4 days after the last dose of molnupiravir.

- Lactation: Breast-feeding is not recommended during treatment and for 4 days after the last dose of molnupiravir. For men of reproductive age, use appropriate and effective contraception during treatment and for at least 3 months after the last dose of monulpiravir.

- Detailed information on drugs shall comply with the drug instruction sheet approved by the Ministry of Health.